BioSpace News Archive

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference on Wednesday, July 20, 2022.

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets day on August 3.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022.

Orthofix Medical Inc . (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and LimaCorporate S.p.A., a global orthopedic company focused on digital innovation and patient-tailored hardware, today announced a licensing partnership for the U.S. market to provide a novel solution for patients with the challenging condition of chronic high dislocation of the hip.

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to sell approximately 16.6 million shares of its common stock to a select group of institutional and accredited investors in a private placement, at a price per share of $7.21.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2022 second quarter earnings conference call on Tuesday, August 9, 2022 at 8:30 a.m. ET.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022.

Apollo Endosurgery, Inc. announced today the marketing authorization of the Apollo ESG TM, Apollo ESG Sx TM, Apollo REVISE TM and Apollo REVISE Sx TM Systems through the U.S. Food and Drug Administration’s (FDA) De Novo Classification process, a rigorous pre-market review pathway for low-to moderate-risk devices without a predicate.

Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway.